Literature DB >> 22866097

Silencing of anti-apoptotic transmembrane protein lifeguard sensitizes solid tumor cell lines MCF-7 and SW872 to perifosine-induced cell death activation.

Vesna Bucan1, Claudia Y U Choi, Andrea Lazaridis, Peter M Vogt, Kerstin Reimers.   

Abstract

Lifeguard (LFG), an anti-apoptotic protein with high expression rates in breast cancer cells, has been identified as a molecule that inhibits death mediated by Fas. The molecular function of LFG and its regulation in the carcinogenesis of human breast and sarcoma cells, however, remains to be elucidated. In the present study, we investigated the ability of LFG expression to inhibit apoptosis induced by the alkyl-phospholipid perifosine. Results showed that LFG was able to be downregulated in selected sarcoma and breast cancer cell lines characterized by high endogenous LFG expression. A decreased LFG expression led to enhanced sensitivity to treatment with an agonistic Fas antibody or treatment with perifosine. Taken together, our findings indicate the role of LFG as an anti-apoptotic protein and provide further evidence of the potential of LFG as a target for the development of novel therapeutic strategies.

Entities:  

Year:  2011        PMID: 22866097      PMCID: PMC3410496          DOI: 10.3892/ol.2011.285

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  24 in total

1.  Perifosine, a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest.

Authors:  Vyomesh Patel; Tyler Lahusen; Terence Sy; Edward A Sausville; J Sivio Gutkind; Adrian M Senderowicz
Journal:  Cancer Res       Date:  2002-03-01       Impact factor: 12.701

2.  In vitro and In vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts.

Authors:  Faustino Mollinedo; Janis de la Iglesia-Vicente; Consuelo Gajate; Ander Estella-Hermoso de Mendoza; Janny A Villa-Pulgarin; Mercè de Frias; Gaël Roué; Joan Gil; Dolors Colomer; Miguel A Campanero; Maria J Blanco-Prieto
Journal:  Clin Cancer Res       Date:  2010-03-16       Impact factor: 12.531

3.  The effect of antisense Bcl-2 oligonucleotides on Bcl-2 protein expression and apoptosis in human bladder transitional cell carcinoma.

Authors:  B J Duggan; P Maxwell; J D Kelly; P Canning; N H Anderson; P F Keane; S R Johnston; K E Williamson
Journal:  J Urol       Date:  2001-09       Impact factor: 7.450

4.  Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts.

Authors:  Consuelo Gajate; Faustino Mollinedo
Journal:  Blood       Date:  2006-09-26       Impact factor: 22.113

5.  FasL (CD95L/APO-1L) resistance of neurons mediated by phosphatidylinositol 3-kinase-Akt/protein kinase B-dependent expression of lifeguard/neuronal membrane protein 35.

Authors:  Christoph P Beier; Jörg Wischhusen; Marc Gleichmann; Ellen Gerhardt; Ana Pekanovic; Andreas Krueger; Verdon Taylor; Ueli Suter; Peter H Krammer; Matthias Endres; Michael Weller; Jörg B Schulz
Journal:  J Neurosci       Date:  2005-07-20       Impact factor: 6.167

6.  LFG: a candidate apoptosis regulatory gene family.

Authors:  Lan Hu; Temple F Smith; Gabriel Goldberger
Journal:  Apoptosis       Date:  2009-11       Impact factor: 4.677

7.  Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway.

Authors:  Gerald A Ruiter; Shuraila F Zerp; Harry Bartelink; Wim J van Blitterswijk; Marcel Verheij
Journal:  Anticancer Drugs       Date:  2003-02       Impact factor: 2.248

8.  A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial.

Authors:  M Knowling; M Blackstein; R Tozer; V Bramwell; J Dancey; N Dore; S Matthews; E Eisenhauer
Journal:  Invest New Drugs       Date:  2006-09       Impact factor: 3.850

9.  Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation.

Authors:  Sudhir B Kondapaka; Sheo S Singh; Girija P Dasmahapatra; Edward A Sausville; Krishnendu K Roy
Journal:  Mol Cancer Ther       Date:  2003-11       Impact factor: 6.261

10.  The anti-apoptotic protein lifeguard is expressed in breast cancer cells and tissues.

Authors:  Vesna Bucan; Kerstin Reimers; Claudia Yu Choi; Mau-Thek Eddy; Peter M Vogt
Journal:  Cell Mol Biol Lett       Date:  2010-03-19       Impact factor: 5.787

View more
  5 in total

Review 1.  TMBIM protein family: ancestral regulators of cell death.

Authors:  D Rojas-Rivera; C Hetz
Journal:  Oncogene       Date:  2014-02-24       Impact factor: 8.756

2.  TRIM21, a negative modulator of LFG in breast carcinoma MDA-MB-231 cells in vitro.

Authors:  Judith Müller; Viktor Maurer; Kerstin Reimers; Peter M Vogt; Vesna Bucan
Journal:  Int J Oncol       Date:  2015-09-16       Impact factor: 5.650

3.  Role of lifeguard β-isoform in the development of breast cancer.

Authors:  Nadjib Dastagir; Andrea Lazaridis; Khaled Dastagir; Kerstin Reimers; Peter M Vogt; Vesna Bucan
Journal:  Oncol Rep       Date:  2014-07-25       Impact factor: 3.906

4.  Anti-apoptotic protein Lifeguard does not act as a tumor marker in breast cancer.

Authors:  Viktor Maurer; Kerstin Reimers; Hans J Lück; Peter M Vogt; Vesna Bucan
Journal:  Oncol Lett       Date:  2017-01-27       Impact factor: 2.967

5.  In-Vitro Application of Magnetic Hybrid Niosomes: Targeted siRNA-Delivery for Enhanced Breast Cancer Therapy.

Authors:  Viktor Maurer; Selin Altin; Didem Ag Seleci; Ajmal Zarinwall; Bilal Temel; Peter M Vogt; Sarah Strauß; Frank Stahl; Thomas Scheper; Vesna Bucan; Georg Garnweitner
Journal:  Pharmaceutics       Date:  2021-03-16       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.